Home » Topics » Infection » HIV/AIDS

HIV/AIDS
RSS

NNRTI with potent activity against mutant and wild-type enzymes

Sep. 30, 2002

HHS patents new antiretroviral series

Sep. 26, 2002

First regulatory filing for an HIV fusion inhibitor

Sep. 17, 2002

Merck & Co. discloses HIV integrase inhibitors

Sep. 4, 2002

Fuzeon early access program opens in the U.S.

Aug. 30, 2002

Merck & Co. discloses novel HIV protease inhibitors

Aug. 20, 2002

Fuzeon (T-20) set for launch in 2003

Aug. 9, 2002

Novel anti-HIV agents presented by AIDS Care Pharma

Aug. 7, 2002

Coviracil phase III interim results

Aug. 5, 2002

Immune Network and AbNovo to develop antibody-based therapeutics for viral diseases

Aug. 1, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...